Evidence Intelligence™
- EvidenceScore™
- 86
- Strong
- ImpactScore™
- 76
- Positive
- ConsistencyScore™
- 92
- consistent
Supporting studies: Based on 13 studies
Add to Evidence TrackerResearch Summary
Analyzed using Evidence Intelligence™
Oral semaglutide effectively lowers HbA1c and body weight in T2D patients.
Last updated September 12, 2026
Key finding
HbA1c decreased by 1.0 to 1.5% with oral semaglutide.
This study evaluated the efficacy and safety of oral semaglutide in patients with Type 2 diabetes through a post-hoc analysis.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Extended (5–20+ y)
Risk of bias
High Risk
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the efficacy and safety of oral semaglutide in patients with Type 2 diabetes through a post-hoc analysis.
Clinical relevance
These findings are significant for clinicians treating Type 2 diabetes, as they suggest that oral semaglutide can effectively improve glycemic control and promote weight loss. This could enhance patient adherence to treatment and overall management of diabetes, potentially leading to better long-term health outcomes.
Keep in mind
The study did not provide specific p-values for some outcomes. The analysis was post-hoc, which may limit the robustness of the findings. Generalizability may be limited due to the specific population studied.
Published in
Journal Reference
Publication details and source links for this paper.
Richard EP, Matthew JC, Mette G, et al. Efficacy and Safety of Oral Semaglutide in Patients with Type 2 Diabetes: A Post-hoc Analysis. Diabetes Therapy. 2021;12(4):1099-1116. doi:10.1007/s13300-020-00994-9
Main Effects
Oral semaglutide reduced HbA1c by 1.25% (p-value: null).
Body weight decreased by 3.6 kg with oral semaglutide (p-value: null).
No significant interactions were found for HbA1c change with comparator treatments.
No significant interactions were found for body weight change with comparator treatments.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Semaglutide, Standard treatment and Body weight, Gastrointestinal disorders incidence, HbA1c.
This study contributes evidence to
Primary intervention
Semaglutide
Primary outcomes
- Body weight
- Gastrointestinal disorders incidence
- HbA1c
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
5
Evidence pairs
5
Relationships
4
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 68
4
Related topics
5
Evidence pairs
1300
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 5 evidence relationships
- Includes primary outcome data
- Linked to 4 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Add related evidence to your Evidence Tracker
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
GLP-1 Receptor Agonists and HbA1c
Related evidence
Evidence relationship
GLP-1 Receptor Agonists and Body Weight
Save evidence
Evidence relationship
GLP-1 Receptor Agonists and Gastrointestinal Adverse Events
Save evidence
Core evidence
Study findings
The primary outcomes reported in this study.
Gastrointestinal disorders incidence
Semaglutide → Gastrointestinal disorders incidence
Semaglutide → Gastrointestinal disorders incidence
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 2 studies
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 88
- Strong
- ImpactScore™
- 87
- Very Positive
- ConsistencyScore™
- 88
- consistent
Supporting studies: Based on 16 studies
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Strong
- Score 79 · Based on 3 studies
- ImpactScore™
- 67
- Slightly Positive
- ConsistencyScore™
- 67
- generally_consistent
Supporting studies: Based on 3 studies
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Strong
- Score 79 · Based on 3 studies
- ImpactScore™
- 67
- Slightly Positive
- ConsistencyScore™
- 67
- generally_consistent
Supporting studies: Based on 3 studies
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Evidence Suggest
- Oral semaglutide decreased HbA1c by 1.25%.
- Body weight decreased by 3.6 kg with oral semaglutide.
- No significant differences were observed in outcomes with comparator treatments.
Who this applies to
- Adults with Type 2 diabetes.
- Patients looking for oral medication options for diabetes management.
Keep in Mind
- The study's findings are based on a post-hoc analysis.
- Results may not be applicable to all demographics or diabetes types.
- Further research is needed to confirm these findings in broader populations.
Between the Lines
- The study did not provide specific p-values for some outcomes.
- The analysis was post-hoc, which may limit the robustness of the findings.
- Generalizability may be limited due to the specific population studied.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and HbA1c, GLP-1 Receptor Agonists and Body Weight.
Related evidence relationships
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
GLP-1 Receptor Agonists → HbA1c
Medications
Evidence Intelligence™
- EvidenceScore™
- 88
- Strong
- ImpactScore™
- 87
- Very Positive
- ConsistencyScore™
- 88
- consistent
Supporting studies: Based on 16 studies
View evidenceMedications
GLP-1 Receptor Agonists → Body Weight
Medications
Evidence Intelligence™
- EvidenceScore™
- 86
- Strong
- ImpactScore™
- 76
- Positive
- ConsistencyScore™
- 92
- consistent
Supporting studies: Based on 13 studies
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
GLP-1 Receptor Agonists Evidence Hub
All studies on GLP-1 Receptor Agonists
16 studies
intervention_hubContributes to GLP-1 Receptor Agonists evidence base.
HbA1c Evidence Hub
All studies measuring HbA1c
16 studies
outcome_hubMeasures HbA1c as a key outcome.
Body Weight Evidence Hub
All studies measuring Body Weight
13 studies
outcome_hubMeasures Body Weight as a key outcome.
Explore more in Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Semaglutide and HbA1c
Intervention: SemaglutideOutcome: HbA1c
16 results
All studies on Semaglutide and Body weight
Intervention: SemaglutideOutcome: Body weight
13 results
All studies on Semaglutide
Intervention: Semaglutide
16 results
All studies measuring HbA1c
Outcome: HbA1c
16 results
All studies measuring Body weight
Outcome: Body weight
13 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Do GLP-1 Receptor Agonists lower HbA1c?
Strong Evidence
GLP-1 Receptor Agonists appear to lower HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 88.2 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 45 supporting studies with consistent results and a positive effect signal.
Do GLP-1 Receptor Agonists affect body weight?
Strong Evidence
GLP-1 Receptor Agonists may affect body weight.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Strong | EvidenceScore™ 85.8 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 43 supporting studies with consistent results and a positive effect signal.
Do GLP-1 Receptor Agonists affect gastrointestinal adverse events?
Strong Evidence
Current evidence does not show a clear effect of GLP-1 Receptor Agonists on gastrointestinal adverse events.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Gastrointestinal disorders incidence
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | neutral | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 12 supporting studies and existing graph evidence signals.
Does Standard treatment affect body weight?
Strong Evidence
Standard treatment may affect body weight.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Strong | EvidenceScore™ 79.0 | weak positive | ConsistencyScore™ Generally Consistent | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Semaglutide may reduce cardiovascular events in non-diabetic patients.Oral semaglutide reduces cardiovascular events in type 2 diabetesSemaglutide improves insulin sensitivity in adolescents with obesityHigher semaglutide doses improve glucose control in type 2 diabetesNovel Semaglutide Injection Shows Non-Inferior Glycemic Control
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.